SPRINKLR INC-A (CXM)       10.405  +0 (+0.05%)

10.405  +0 (+0.05%)

US85208T1079 - Common Stock


Fundamental Rating

4

Taking everything into account, CXM scores 4 out of 10 in our fundamental rating. CXM was compared to 373 industry peers in the Software industry. While CXM has a great health rating, but there are worries on its profitability. CXM is valued quite expensive, but it does show an excellent growth.

Note: CXM has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

1

The Piotroski-F score of CXM is 4.00. This is a neutral score and indicates average health and profitability for CXM.

VS Industry

Valuation

Valuation Rating

2

The PEG Ratio, which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
With a price book ratio of 5.25, CXM is valued correctly.
The Price/Earnings Ratio is negative for CXM. In the last year negative earnings were reported.

With a Forward Price/Earnings Ratio of 114.58, CXM is valued very expensively.
Compared to an average industry price book ratio of 3.41, CXM is valued more expensive than its industry peers.
VS Industry

Price/Book (5.25) VS Industry: 34% outperformed.

195.25
0.11

Growth

Growth Rating

7

CXM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.12%, which is quite good.
Based on estimates for the next 5 years, CXM will show a very strong growth in Earnings Per Share. The EPS will grow by 37.20% on average per year.

The Revenue has grown by 27.71% in the past year. This is a very strong growth!
CXM is expected to show quite a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 19.76% yearly.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 12.12% 85.13% 51.52% 37.2% N/A
RevenueN/A N/A 27.71% 26.39% 20.7% 19.76% N/A

Health

Health Rating

7

CXM has a Current Ratio of 2.06. This indicates that CXM is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 2.06 indicates that CXM has no problem at all paying its short term obligations.
When comparing the Debt to Equity Ratio of 0.00 to an average industry Debt to Equity of 0.06, CXM is way less dependent on financing that its industry peers.
An Altman-Z score of 4.43 indicates that CXM is not in any danger for bankruptcy at the moment.

CXM is in better financial health than average in its industry. Its Altman-Z score is much better than the industry average of 1.79.
CXM has a Current Ratio comparable to the industry average, which is at 1.76.
CXM has a Quick Ratio comparable to the industry average, which is at 1.74.
The Piotroski-F score of CXM is 4.00. This is a neutral score and indicates average health and profitability for CXM.
VS Industry

Debt/Equity (0) VS Industry: 66% outperformed.

51.02
0.00

Quick Ratio (2.06) VS Industry: 57% outperformed.

0.06
83.89

Current Ratio (2.06) VS Industry: 56% outperformed.

0.06
83.89

Altman-Z (4.43) VS Industry: 69% outperformed.

-485.88
215.75

Dividend

Dividend Rating

0

No dividends for CXM!.

SPRINKLR INC-A10.405

NYSE:CXM (2/2/2023, 9:04:59 AM)+0 (+0.05%)

Chartmill FA Rating
GICS Sector Information Technology
GICS IndustryGroup Software & Services
GICS Industry Software
Earnings (Last) 12-06 2022-12-06/amc Earnings (Next) N/A N/A
Inst Owners 25.77% Inst Owner Change -0.02%
Ins Owners 1.2% Ins Owner Change -161.6%
Market Cap 2.72B Analysts 77.33
Price Target 11.09 (6.58%)

Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A

Surprises & Revisions
EPS beat(2) 2 Avg EPS beat(2) 160.38%
Min EPS beat(2) 47.05% Max EPS beat(2) 273.7%
EPS beat(4) 4 Avg EPS beat(4) 96.46%
Min EPS beat(4) 21.79% Max EPS beat(4) 273.7%
Revenue beat(2) 1 Avg Revenue beat(2) 0.51%
Min Revenue beat(2) -0.23% Max Revenue beat(2) 1.24%
Revenue beat(4) 3 Avg Revenue beat(4) 1.44%
Min Revenue beat(4) -0.23% Max Revenue beat(4) 3.03%
PT rev (1m) -0.13% PT rev (3m) -26.89%
EPS NQ rev (1m) 37.72% EPS NQ rev (3m) 37.72%
EPS NY rev (1m) 0% EPS NY rev (3m) 38.86%
Revenue NQ rev (1m) -2% Revenue NQ rev (3m) -2%
Revenue NY rev (1m) 0% Revenue NY rev (3m) -0.38%

Valuation
Industry RankSector Rank
PE N/A
Fwd PE 114.58
P/S 4.62
P/FCF N/A
P/OCF N/A
P/B 5.25
P/tB 5.82
EV/EBITDA N/A
EPS(TTM) -0.11 EY N/A
EPS(NY) 0.09 Fwd EY 0.87%
FCF(TTM) -0.09 FCFY N/A
OCF(TTM) -0.04 OCFY N/A
SpS 2.25 BVpS 1.98
TBVpS 1.79 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM 72.1%
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y N/A GM growth 5Y N/A
F-Score 4 Asset Turnover 0.66

Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 123.04%
Profit Quality N/A
Current Ratio 2.06
Quick Ratio 2.06
Altman-Z 4.43
F-Score 4 WACC 10.9%
ROIC/WACC N/A Cap/Depr(3y) 128.3%
Cap/Depr(5y) N/A Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y 12.12% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 133.33%
EPS Next Y 85.13% EPS Next 2Y 51.52%
EPS Next 3Y 37.2% EPS Next 5Y N/A
Revenue growth 1Y 27.71% Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q 23.77%
Revenue Next Year 26.39% Revenue Next 2Y 20.7%
Revenue Next 3Y 19.76% Revenue Next 5Y N/A
EBIT growth 1Y 0.48% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year 120.99%
EBIT Next 3Y 31.79% EBIT Next 5Y N/A
FCF growth 1Y -5581.02% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y -550.31%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA